Brano Therapeutics, a biotechnology spin-off from Duke-NUS Medical School, has successfully secured US$6.8 million in a recent seed funding round. The investment was co-led by Trinity Innovation Bioventure Singapore (TIBS) and SEEDS, signaling strong confidence in the company's innovative approach. This capital infusion is earmarked to advance the development of novel treatments for heart failure, particularly for conditions with limited therapeutic options.
Addressing a Critical Unmet Need
Heart failure represents a significant and growing global health challenge, affecting an estimated 64 million people worldwide. A specific form, Heart Failure with preserved Ejection Fraction (HFpEF), is becoming more prevalent due to aging populations and rising rates of related conditions. Despite its increasing impact, effective treatment options for HFpEF remain severely limited, creating an urgent need for new therapies.
The scientific foundation for Brano's work originates from pioneering research conducted by scientists at Duke-NUS. Their studies identified a distinct metabolic abnormality in HFpEF patients where the heart struggles to process key nutrients efficiently. This dysfunction leads to the accumulation of harmful by-products in the blood, contributing directly to poor cardiac function and worse clinical outcomes.
In a promising proof-of-concept study, researchers demonstrated that targeting this metabolic pathway has significant therapeutic potential. Treatment with a specialized compound successfully restored metabolic regulation in a preclinical experimental model. This intervention led to a notable reduction in heart stiffness and an overall improvement in heart function, validating the company's core strategy.
Strategic Investment and Ecosystem Growth
The US$6.8 million investment round saw participation from SGInnovate and Duke-NUS’s own early-stage fund, LIVE VENTURES, alongside the lead investors. This diverse backing underscores a collective belief in Brano's innovative approach and its potential to transform cardiovascular medicine. The funding provides the necessary resources to advance the company's research from the laboratory toward clinical application.
Langdon Wu, Managing Director at TIBS, expressed pride in partnering with Brano to build a high-impact cardiovascular innovation company founded on world-class research. This investment marks TIBS's fifth in a local spin-off, reinforcing its commitment to nurturing Singapore's life sciences ecosystem. The collaboration bridges academic research with disciplined commercial strategy to create meaningful biotech solutions for global health challenges.
The funding round also highlights strong institutional support, with Duke-NUS's LIVE Ventures making its first direct investment in a spin-off company. This commitment, along with backing from SEEDS, an arm of SG Growth Capital, demonstrates a strategic effort to translate scientific discoveries into viable commercial pathways. This collaborative model is crucial for fostering innovation from academic institutions into the market.
The Path Toward Clinical Application
With the new capital, Brano Therapeutics is set to accelerate the development of its novel and potent compounds. The company's primary focus is on creating medicines that specifically target the metabolic dysfunction observed in heart failure patients. This targeted approach aims to address a root cause of the disease rather than just managing its symptoms.
Looking ahead, Brano has established a clear roadmap for bringing its innovative therapy from the bench to the bedside. The company aims to advance its therapeutic approach into clinical trials by 2029, a significant milestone in its development pipeline. The ultimate objective is to introduce a next-generation treatment that redefines the standard of care for heart failure.
This successful seed funding round marks a pivotal moment for Brano Therapeutics and the broader fight against cardiovascular disease. The investment not only validates the company's groundbreaking scientific approach but also provides the fuel for its journey toward clinical trials. As Brano advances its work, it holds the potential to deliver life-changing therapies for patients and further solidify Singapore's position as a global biotech hub.